JavaScript est désactivé dans votre navigateur Internet

Pour accéder à toutes les fonctionnalités de ce site, vous devez activer JavaScript.
Ensuite, actualiser cette page pour supprimer ce message.

Comment activer JavaScript

Canadian clinical trial registry

Keywords (including molecular targets)

Diagnosis

Line of treatment

Age (in years)

Study Status

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

1 results found

Title

Status

IGNYTE-ESO - Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Closed to enrollment

More information

Go to Health Care Provider version

Diagnosis	Advanced tumors	Study Status	Closed to enrollment
Phase	II
Age	10 Years and older	Randomisation	NO
Line of treatment	First line treatment, Disease relapse or progression
Routes of Treatment Administration	Drug: Letetresgene autoleucel (lete-cel, GSK3377794) letetresgene autoleucel will be administered. Drug: Fludarabine Fludarabine will be used as the lymphodepleting chemotherapy Drug: Cyclophosphamide Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Last Posted Update	2024-04-09
ClinicalTrials.gov #	NCT03967223

International Sponsor

GlaxoSmithKline

Principal Investigators for Canadian Sites

Maisonneuve-Rosemont Hospital

Centres

Maisonneuve-Rosemont Hospital

Medical contact

N/A

Social worker/patient navigator contact

N/A

Clinical research contact

N/A

Study Description

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumours.

Inclusion Criteria

Participant must be greater than or equal to 10 years of age on the day of signing informed consent.
Participant has a diagnosis of synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)
Participant should be up and about 60% of their waking hours with minimal to no restrictions
Participant must meet the lab and organ function requirements prior to starting study

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team